Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation
Frontiers in Pharmacology · 02.04.2025 · 16
DOI: 10.3389/fphar.2025.1514997 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 02.04.2025. Verfasst von Ni Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Curcumol, a bioactive sesquiterpenoid extracted from traditional Chinese medicine (TCM), has demonstrated potential in overcoming tumor drug resistance. However, its mechanisms in reversing drug resistance, particularly in hepatocellular carcinoma (HCC) resistant to sorafenib, are not yet fully elucidated. This study aims to explore the molecular mechanisms by which curcumol reverses sorafenib resistance in HCC using a combination of network pharmacology, molecular docking, and in vivo and in vitro experiments.
Methods
We identified curcumol targets and genes associated with sorafenib-resistant HCC, resulting in a set of overlapping targets. These intersection targets underwent enrichment analysis using DAVID, and a protein-protein interaction (PPI) network was constructed via the STRING database and Cytoscape. Molecular docking confirmed the binding of curcumol to core targets. In vitro assays, including CCK-8, colony formation assay, apoptosis detection, wound healing, and Transwell assays, evaluated curcumol’s effects on sorafenib-resistant HCC cells. Western blotting assessed the impact on PI3K/AKT and JAK/STAT3 signaling pathways. Additionally, a sorafenib-resistant HCC xenograft mouse model was established to observe the in vivo efficacy of curcumol combined with sorafenib.
Results
We identified 117 potential targets for curcumol in reversing sorafenib resistance in HCC. Among them, five core targets—ALB, STAT3, HSP90AA1, HSP90AB1, and SRC—showed strong binding affinity with curcumol. KEGG pathway analysis of the intersecting genes highlighted significant involvement of the PI3K/AKT, JAK/STAT3, Ras, Rap1, HIF-1, FoxO, and mTOR signaling pathways. In vitro experiments revealed that curcumol significantly enhanced the sensitivity of sorafenib-resistant HCC cells to sorafenib, inhibiting cell proliferation, invasion, and migration while promoting apoptosis. In vivo studies further confirmed that curcumol combined with sorafenib effectively inhibited tumor growth in sorafenib-resistant HCC models.
Conclusion
This study provides compelling evidence that curcumol can reverse sorafenib resistance in HCC by modulating multiple signaling pathways, including PI3K/AKT and JAK/STAT3 pathways. Our findings suggest that curcumol holds promise as a novel therapeutic agent for overcoming drug resistance in HCC, offering a new avenue for clinical intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
- Clinical Medical Laboratory Center, Jining First People's Hospital, Jining Medical University, Jining, Shandong, China.
- Institute of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, Shandong, China.
- Jining No. 1 People's Hospital, Shandong First Medical University, Jining, China.
- Center for Post-Doctoral Studies, Shandong University of Traditional Chinese Medicine, Jinan, China.
Zitieren
APA
Zhang, N., Tian, X., Liu, F., Jin, X., Zhang, J., Hao, L., Jiang, S., & Liu, Q. (2025). Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1514997
Vancouver
Zhang N, Tian X, Liu F, Jin X, Zhang J, Hao L, et al. Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1514997
BibTeX
@article{Zhang2025,
author = {Zhang, Ni and Tian, Xinchen and Liu, Fen and Jin, Xiaohan and Zhang, Jiaqi and Hao, Lingli and Jiang, Shulong and Liu, Qingbin},
title = {Reversal of sorafenib resistance in hepatocellular carcinoma by curcumol: insights from network pharmacology, molecular docking, and experimental validation},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {16},
doi = {10.3389/fphar.2025.1514997}
}
EUVIMED